{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:49:25Z","timestamp":1791992965342,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zentiva"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07211-w","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:23:06Z","timestamp":1785388986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between proton pump inhibitor co-medication and treatment switching in dasatinib-treated patients with chronic myeloid leukemia: a German real-world evidence study"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-3058","authenticated-orcid":false,"given":"Sabrina","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2710-3259","authenticated-orcid":false,"given":"Chen-Chia","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7776-1088","authenticated-orcid":false,"given":"Jan","family":"Bos\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5438-4773","authenticated-orcid":false,"given":"Florian O.","family":"Losch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-6426","authenticated-orcid":false,"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-8080","authenticated-orcid":false,"given":"Barthold","family":"Deiters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-8148","authenticated-orcid":false,"given":"Daniela","family":"\u017d\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"7211_CR1","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian H (2025) Chronic myeloid leukemia: a review. JAMA 333(18):1618\u20131629. https:\/\/doi.oeg\/10.1001\/jama.2025.0220","DOI":"10.1001\/jama.2025.0220"},{"key":"7211_CR2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/J.CCELL.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ (2020) Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell 37:530. https:\/\/doi.org\/10.1016\/J.CCELL.2020.03.006","journal-title":"Cancer Cell"},{"key":"7211_CR3","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM-L (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851\u20132857","journal-title":"J Clin Oncol"},{"key":"7211_CR4","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/BLOODADVANCES.2019001329","volume":"4","author":"C Vener","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F, Ferrero A, Saglio G, Pravettoni G et al (2020) First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv 4:2723. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2019001329","journal-title":"Blood Adv"},{"key":"7211_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","volume":"59","author":"D Lev\u00eaque","year":"2020","unstructured":"Lev\u00eaque D, Becker G, Bilger K, Natarajan-Am\u00e9 S (2020) Clinical pharmacokinetics and pharmacodynamics of dasatinib. Clin Pharmacokinet 59:849\u2013856","journal-title":"Clin Pharmacokinet"},{"key":"7211_CR6","doi-asserted-by":"publisher","unstructured":"Andersson P, Brisander M, Liljebris C, Jesson G, Lennern\u00e4s H (2024) Severe Impact of Omeprazole Timing on pH-Sensitive Dasatinib Absorption: Unveiling Substantial Drug\u2013Drug Interaction. J Clin Pharmacol 65. https:\/\/doi.org\/10.1002\/JCPH.6173","DOI":"10.1002\/JCPH.6173"},{"key":"7211_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/EJH.14059","volume":"111","author":"G Larfors","year":"2023","unstructured":"Larfors G, Andersson P, Jesson G, Liljebris C, Brisander M, Lennern\u00e4s H et al (2023) Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug\u2013drug interactions. Eur J Haematol 111:644\u2013654. https:\/\/doi.org\/10.1111\/EJH.14059","journal-title":"Eur J Haematol"},{"key":"7211_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/cncr.31917","volume":"125","author":"M Sharma","year":"2019","unstructured":"Sharma M, Holmes HM, Mehta HB, Chen H, Aparasu RR, Shih YT et al (2019) The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer 125:1155\u20131162","journal-title":"Cancer"},{"key":"7211_CR9","doi-asserted-by":"publisher","first-page":"675609","DOI":"10.3389\/fonc.2021.675609","volume":"11","author":"M Pajiep","year":"2021","unstructured":"Pajiep M, Conte C, Huguet F, Gauthier M, Despas F, Lapeyre-Mestre M (2021) Patterns of tyrosine kinase inhibitor utilization in newly treated patients with chronic myeloid leukemia: an exhaustive population-based study in France. Front Oncol 11:675609","journal-title":"Front Oncol"},{"key":"7211_CR10","doi-asserted-by":"publisher","unstructured":"Lapka M, Khryakova A, Nazmutdinova A, Charalambous C, Bosak J, Sliva J Prescription Behaviour and Drug Interactions of Acid Suppressants With Tyrosine Kinase Inhibitors in Patients With Leukaemia: Data From Germany. EJHaem 2026;7:e70279. https:\/\/doi.org\/10.1002\/jha2.70279","DOI":"10.1002\/jha2.70279"},{"key":"7211_CR11","doi-asserted-by":"publisher","unstructured":"Dahl\u00e9n T, Larfors G, Lennern\u00e4s H, Liljebris C, Von Euler M, Brisander M et al (2024) Frequency of comedication of proton pump inhibitors with crystalline dasatinib in chronic myeloid leukemia and effects on TKI-bioavailability. J Clin Oncol 42:6561\u20136561 https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.6561","DOI":"10.1200\/JCO.2024.42.16_suppl.6561"},{"key":"7211_CR12","doi-asserted-by":"crossref","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H et al (2025) 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia: CHRONIC MYELOID LEUKEMIA. Leukemia. ;39:1797\u2013813","DOI":"10.1038\/s41375-025-02664-w"},{"key":"7211_CR13","doi-asserted-by":"publisher","first-page":"1113462","DOI":"10.3389\/fonc.2023.1113462","volume":"13","author":"F Cheng","year":"2023","unstructured":"Cheng F, Xu Q, Li Q, Cui Z, Li W, Zeng F (2023) Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. Front Oncol 13:1113462","journal-title":"Front Oncol"},{"key":"7211_CR14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130\u20131139","journal-title":"Med Care"},{"key":"7211_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000321525","volume":"117","author":"J-W Chae","year":"2011","unstructured":"Chae J-W, Song CS, Kim H, Lee K-B, Seo B-S, Kim D-I (2011) Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity Index using ICD-10 database. Nephron Clin Pract 117:379\u2013384","journal-title":"Nephron Clin Pract"},{"key":"7211_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-025-01242-8","volume":"15","author":"L Busque","year":"2025","unstructured":"Busque L, Beaudet M-\u00c9, Harnois M, Moussa H, Szuber N, Mollica L et al (2025) Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study. Blood Cancer J 15:35. https:\/\/doi.org\/10.1038\/s41408-025-01242-8","journal-title":"Blood Cancer J"},{"key":"7211_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","volume":"14","author":"M Brave","year":"2008","unstructured":"Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S et al (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome\u2013positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14:352\u2013359","journal-title":"Clin Cancer Res"},{"key":"7211_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.clml.2024.02.014","volume":"24","author":"FG Haddad","year":"2024","unstructured":"Haddad FG, Nasnas C, Sasaki K, Paul S, Issa GC, Rausch C et al (2024) Using proton pump inhibitors is not associated with adverse outcomes in patients with chronic myeloid leukemia treated with dasatinib. Clin Lymphoma Myeloma Leuk 24:484\u2013487","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7211_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12185-020-02845-6","volume":"111","author":"K Yoshimichi","year":"2020","unstructured":"Yoshimichi K, Taniguchi J, Naoko Y, Hiroki N, Tomoaki E, Kotaro N et al (2020) Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients. Int J Hematol 111:826\u2013832","journal-title":"Int J Hematol"},{"key":"7211_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000524284","volume":"45","author":"S Sau\u00dfele","year":"2022","unstructured":"Sau\u00dfele S, Kohlbrenner K, Vogelmann T, Schubert T, Incidence (2022) Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis. Oncol Res Treat 45:400\u2013407. https:\/\/doi.org\/10.1159\/000524284","journal-title":"Oncol Res Treat"},{"key":"7211_CR21","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/s41375-020-0931-9","volume":"34","author":"M Pfirrmann","year":"2020","unstructured":"Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S et al (2020) The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia 34:2138\u20132149","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07211-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07211-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07211-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:11Z","timestamp":1786785611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07211-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7211"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07211-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was a non-interventional, retrospective analysis of anonymized secondary data derived from German statutory health insurance claims. In accordance with applicable German data protection regulations, only anonymized data were available to the investigators, and no direct patient contact occurred. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and applicable regulations governing the use of anonymized secondary healthcare data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was not required for this study because it was based exclusively on anonymized German statutory health insurance claims data. No direct contact with patients occurred, and no identifiable personal data were available to the investigators.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Zentiva, a.s., Prague, Czech Republic. Authors JB, JH, and FL are employees of Zentiva. CP is an employee of GIPAM GmbH. SM and TW are shareholders of GIPAM GmbH. GIPAM GmbH was contracted by Zentiva for the conduct of this study. BD is an employee of GWQ ServicePlus AG, which provided the anonymized research data used for this study. DZ has received compensation from Zentiva for consulting and Scientific Advisory Board participation. The authors declare no further competing interests.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"351"}}